Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Reinforcing commitment to ethical and sustainable growth
The agreement complements other PPAs for Sandoz production sites globally
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Ranks among the top 15% companies globally
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
FlexiTubes will showcase range of eco-friendly and innovative tube options
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
This rating reflects Lupin's leadership in environmental transparency and performance
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Subscribe To Our Newsletter & Stay Updated
